Experience

Pacira BioSciences, Inc.

• United States
• Pharmaceutical Manufacturing
• 500 - 600 Employee

• Management Team

  • Jul 2008 - Present

  Pacira is passionate about delivering and improving patient care. We focus our clinical and commercial development activities by understanding the needs of the acute care market. Our mission is to cost-effectively enhance the care of patients by translating our core technologies into new products that address the needs of acute care patients, health care providers and payers. We leverage the experience and expertise of our management team to create value in our products, pipeline programs, and… Show more Pacira is passionate about delivering and improving patient care. We focus our clinical and commercial development activities by understanding the needs of the acute care market. Our mission is to cost-effectively enhance the care of patients by translating our core technologies into new products that address the needs of acute care patients, health care providers and payers. We leverage the experience and expertise of our management team to create value in our products, pipeline programs, and partnerships for the markets we serve as well as for our stakeholders. EXPAREL™ is designed to extend the duration of analgesia provided by the commonly used local analgesic, bupivacaine. By prolonging the effective dose of bupivacaine from 6 - 8 hours to several days, EXPAREL is expected to provide pain relief for the first few days following surgery when pain is most debilitating.

• VP, Medical Education and Scientific Affairs

  • Aug 2008 - Jun 2009

  Pacira is an acute care specialty pharmaceutical company with a primary focus on developing products which satisfy the needs of our customers in the institutional marketplace. The Company utilizes DepoFoam(R) delivery technology to cost-effectively improve patient care through enhanced dosing and administration profiles. Currently, the Company is developing DepoBupivacaine(TM) in phase III clinical studies for postsurgical pain. Revenues are generated from two approved products which are… Show more Pacira is an acute care specialty pharmaceutical company with a primary focus on developing products which satisfy the needs of our customers in the institutional marketplace. The Company utilizes DepoFoam(R) delivery technology to cost-effectively improve patient care through enhanced dosing and administration profiles. Currently, the Company is developing DepoBupivacaine(TM) in phase III clinical studies for postsurgical pain. Revenues are generated from two approved products which are marketed by partners: DepoCyt(R) for lymphomatous meningitis and DepoDur(R) for post-surgical pain. Additional information about Pacira is available at http://www.pacira.com.



AVLES Corporation

• President

  • Jun 2008 - Present

  AVLES Corporation is a full service healthcare and specialty pharmaceuticals consulting firm, with expertise is in developing and delivering commercial solutions by: - better identifying, promoting and proving the value of a particular drug to key stakeholders - discovering new efficiencies - accelerating positive outcomes - reducing unnecessary complexity In a marketplace where the demands of customers, payers and patients are constantly changing, AVLES Corporation has a… Show more AVLES Corporation is a full service healthcare and specialty pharmaceuticals consulting firm, with expertise is in developing and delivering commercial solutions by: - better identifying, promoting and proving the value of a particular drug to key stakeholders - discovering new efficiencies - accelerating positive outcomes - reducing unnecessary complexity In a marketplace where the demands of customers, payers and patients are constantly changing, AVLES Corporation has a broad range of commercial solutions and the flexibility to help you successfully differentiate your products across their lifecycle to relevant worldwide stakeholders. Our end goals - more revenue, better operational efficiency and well utilized resources by providing: Comprehensive Commercial Solutions that meet your needs to help optimize the success of your products throughout development and commercialization. Market Access to identify and demonstrate product value while removing barriers to your success. Strategic utilization of Multiple Communications Channels that deliver the right stakeholder message, at the right time and in the medium with the most impact. When you are ready to make a move and truly move your brand, call David St. Peter, MD at 518.225.7525. Show less



Saratoga Hospital

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Hospitalist

  • Dec 2001 - Present

  DAVID ST. PETER, MD EARNS FELLOW IN HOSPITAL MEDICINE DESIGNATION Philadelphia, PA, [March 10, 2010] -- The Society of Hospital Medicine (SHM) has announced that David St. Peter, MD of Saratoga Hospital and Saratoga Inpatient Physicians, PC is among the more than 150 hospitalists nationwide who have earned the Fellow in Hospital Medicine (FHM) designation in 2010. The FHM credential is a key component in professional development for hospitalists. To be designated as a Fellow in… Show more DAVID ST. PETER, MD EARNS FELLOW IN HOSPITAL MEDICINE DESIGNATION Philadelphia, PA, [March 10, 2010] -- The Society of Hospital Medicine (SHM) has announced that David St. Peter, MD of Saratoga Hospital and Saratoga Inpatient Physicians, PC is among the more than 150 hospitalists nationwide who have earned the Fellow in Hospital Medicine (FHM) designation in 2010. The FHM credential is a key component in professional development for hospitalists. To be designated as a Fellow in Hospital Medicine, an applicant must: - Serve as a hospitalist for at least five years - Be a member of SHM for at least three years, and - Demonstrate their dedication to quality and process improvement, commitment to organizational teamwork and leadership, as well as lifelong learning and education. “As a part of rapidly expanding medical specialty, the best hospitalists in the country are using the FHM designation to better distinguish their expertise and commitment to hospital medicine,” said SHM’s CEO, Larry Wellikson, MD, SFHM. “We hope that hospitals and communities will join us in congratulating these individuals in their achievement and their service to improving patient care in the hospital.” Dr. St. Peter will be inducted as a Fellow at SHM’s annual meeting in Washington, DC on April 10, 2010. ABOUT SHM SHM is the national organization for hospitalists. We are leading the transformation and improvement of care for the hospitalized patient through innovation, collaboration, and action. Over the past decade, studies have shown that hospitalists decrease patient lengths of stay, reduce hospital costs and readmission rates, all while increasing patient satisfaction. Hospital medicine is the fastest-growing specialty in modern healthcare, with over 31,000 hospitalists currently practicing and an upward growth trajectory in full force. For more information about SHM, visit www.hospitalmedicine.org. Show less



Canyon Pharmaceuticals Group

• VP, Commercial Operations

  • Jun 2009 - Jan 2011

  Canyon Pharmaceuticals is a privately held, specialty biopharmaceuticals company focused on delivering innovative therapeutic solutions that target important cellular pathways in thrombosis, tumor growth and metastasis. We connect people and science to delivery life-saving medicines that answer today's unmet medical needs. Canyon holds exclusive world-wide rights to several important therapies, including Iprivask (desirudin for injection), the first subcutaneous (SC) direct thrombin… Show more Canyon Pharmaceuticals is a privately held, specialty biopharmaceuticals company focused on delivering innovative therapeutic solutions that target important cellular pathways in thrombosis, tumor growth and metastasis. We connect people and science to delivery life-saving medicines that answer today's unmet medical needs. Canyon holds exclusive world-wide rights to several important therapies, including Iprivask (desirudin for injection), the first subcutaneous (SC) direct thrombin inhibitor (DTI) for DVT prophylaxis and the prevention of pulmonary emboli. Iprivask is currently available in Europe and the United States. Iprivask was launched into the US market in March 2010, making it the first anticoagulant to enter the US market in nearly 10 years. With a highly experienced clinical, scientific development and commercial team, as well as intimate knowledge of specialty therapeutics within the Acute Care Channel, the team at Canyon truly understands the needs of customers to help deliver practical and innovative treatment solutions that ensure the best possible outcomes. Sound Science and Business Solutions to Advance Today's Standard of Care By consistently applying the most exacting scientific standards, collaborating with leading experts in the scientific community, and rigorously seeking innovative and practical treatment solutions, Canyon Pharmaceuticals has the insights, people, and know-how to advance todays standard of care, providing solutions that greatly improve patient outcomes. Our employees are part of our mission to always deliver highest quality results while working in an entrepreneurial, fast-paced, take-charge environment. So if you would like to join our passion for delivering and optimizing the value of innovative products to the market, please contact us at info@canyonpharma.com to discuss career opportunities. Canyon connects people and science to delivery life-saving medicines that answer today's unmet medical needs. Show less



Canyon Pharmaceuticals

• Medical Affairs

  • Apr 2009 - Feb 2010



Stack Pharmaceuticals, Inc

• Consultant

  • Jul 2008 - Aug 2008



The Selva Group

• President

  • Jan 2006 - Jul 2008



inVentiv Communications

• Executive Team and Operating Board

  • Jan 2006 - Jun 2008

  inVentiv Health, Inc. (NASDAQ: VTIV), a leading provider of end-to-end clinical development, launch and commercialization services to the global pharmaceutical and healthcare industries. We support healthcare brands with integrated solutions by seeing the big picture and delivering customized programs that deliver commercial success. Today's healthcare environment has never been more demanding or more complex. The financial, scientific, social, and practical challenges that surround… Show more inVentiv Health, Inc. (NASDAQ: VTIV), a leading provider of end-to-end clinical development, launch and commercialization services to the global pharmaceutical and healthcare industries. We support healthcare brands with integrated solutions by seeing the big picture and delivering customized programs that deliver commercial success. Today's healthcare environment has never been more demanding or more complex. The financial, scientific, social, and practical challenges that surround healthcare brands are not always simple to understand – and are rarely simple to solve. At inVentiv Health, we see the big picture. Unlike other partners that may approach challenges from only a sales or advertising perspective, we start on neutral ground. First we fully understand and diagnose the issue, then we develop a customized solution to fit your need. With robust resources, inVentiv executes integrated programs designed to grow your brand and enhance your customer relationships. Whether a solution has a few components or many, we orchestrate the tactics to work together seamlessly on your behalf. Show less



inVentiv Health Commercial

• United States
• Pharmaceutical Manufacturing
• 400 - 500 Employee

• Management

  • 2001 - 2008



Palio Communications

• EVP - Managing Director

  • Aug 2001 - Jan 2006



Marion Merrell Dow

• Scientific Information Analysis and Global Commercialization

  • May 1991 - May 1992



Merck

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Hospital Specialty Representative

  • May 1990 - Jan 1991